Agenus Inc (AGEN)

Etorro trading 970x250
Agenus Inc (AGEN) Logo

About Agenus Inc

Agenus Inc., a clinical-stage immuno-oncology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops vaccine programs comprising Prophage vaccine candidate; AutoSynVax, a synthetic neo-antigen; PhosPhoSynVax, a vaccine candidate to treat tumor; and QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that is in Phase II clinical trial to treat second line cervical cancer; AGEN1181, an anti-CTLA-4 monospecific antibody that is in Phase 1/2 clinical trial for dose escalation study; AGEN2373, an anti-CD137 monospecific antibody that is in Phase 1 clinical trial; AGEN1223, a novel bispecific antibody to deplete regulatory T cells, which is in a Phase 1 clinical trial; AGEN-1423, a tumor microenvironment conditioning anti-CD73/TGFß TRAP bi-functional antibody that has completed Phase 1 clinical trial; AGEN1777, an anti-TIGIT bispecific antibodies; and AGEN1327, an anti-TIGIT monospecific antibody. In addition, it develops INCAGN1876, an anti-GITR monospecific antibody; INCAGN1949, an anti-OX40 monospecific antibody; INCAGN2390, an anti-TIM-3 monospecific antibody; INCAGN2385, an anti-LAG-3 monospecific antibody; and MK-4830, a monospecific antibody targeting ILT4, as well as AGENT 797, an iNKT cells that is in Phase 1 clinical trial for the treatment of COVID-19-related pneumonia; and in preclinical stage to treat multiple myeloma/B cell malignancies and solid tumors. The company has collaborations with Incyte Corporation, Merck Sharpe & Dohme, Recepta Biopharma SA, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts. Address: 3 Forbes Road, Lexington, MA, United States, 02421-7305

Agenus Inc News and around…

Latest news about Agenus Inc (AGEN) common stock and company :

Notable Friday Option Activity: AXP, AGEN, SQ
22 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in American Express Co. (AXP), where a total of 57,949 contracts have traded so far, representing approximately 5.8 million underlying shares..

12 Health Care Stocks Moving In Friday's Intraday Session
22 Oct, 2021 FinancialContent

Gainers Progenity (NASDAQ:PROG) stock increased by 18.48% to $2.96 during Friday's regular session. Progenity's ...

35 Stocks Moving In Friday's Mid-Day Session
22 Oct, 2021 FinancialContent

Gainers Phunware, Inc. (NASDAQ: PHUN) rose 1099% to $18.35. Phunware shares jumped over 45% on Thursday, possibly in sympathy with ...

Here's Why Agenus Stock Is Getting Hammered Today
22 Oct, 2021 FinancialContent

The company's experimental anti-PD1 drug hit a wall.

Agenus Provides Update on Balstilimab Development
22 Oct, 2021 Yahoo! Finance

Company voluntarily withdraws BLA at FDA’s recommendation following full approval of pembrolizumab, which came four months earlier than FDA goal dateBalstilimab achieved trial endpoints with 20% response rates in PD-L1 positive patients, versus 14% reported in pembrolizumab’s label; Agenus successfully completed 3 FDA pre-approval inspections for the PDUFA date of Dec. 16, 2021Agenus plans to launch expanded access programs to give patients access to balstilimab in several countries, including t

How The Pieces Add Up: DWAS Targets $103
19 Oct, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the Invesco DWA SmallCap Momentum ETF (DWAS), we found that the implied analyst target price for the ETF based upon its underlying holdings is $102.96 per unit.

First Week of December 17th Options Trading For Agenus (AGEN)
15 Oct, 2021 FinancialContent

Investors in Agenus Inc (AGEN) saw new options become available this week, for the December 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the AGEN options chain for the new December 17th contracts and identified one put and one call contract of particular interest.

Jensen: How to Play Agenus Using Options
13 Oct, 2021 Yahoo! Finance

Agenus , an oncology drug manufacturer, is a good candidate for a simple covered call strategy, argues Real Money's Bret Jensen. This strategy is cheap for investors since the fees for option orders have declined a lot at the majority of brokerages, according to Jensen. "This strategy provides significant downside protection to most holdings within my portfolio," Jensen wrote recently on Real Money.

Agenus to Receive $20M Milestone Payment from Bristol Myers Squibb with Dosing of First Patient with its TIGIT Bispecific Antibody
12 Oct, 2021 Yahoo! Finance

LEXINGTON, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced it has triggered the first development milestone payment under its global licensing agreement with Bristol Myers Squibb for AGEN1777, an Fc-enhanced bispecific anti-TIGIT antibody. Agenus will receive a $20 million cash

2 Stocks Set to Win From the Historic Malaria Vaccine Approval
12 Oct, 2021 FinancialContent

But those wins probably won't be all that big.

Noteworthy Friday Option Activity: EDIT, AGEN, SHAK
08 Oct, 2021 FinancialContent

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Editas Medicine Inc (EDIT), where a total of 11,714 contracts have traded so far, representing approximately 1.2 million underlying shares. That amounts to about 55.5% of EDIT's average daily trading volume over the past month of 2.1 million shares..

Agenus to Present AGEN1181 Clinical Data at SITC
01 Oct, 2021 Yahoo! Finance

LEXINGTON, Mass., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline of checkpoint antibodies, cell therapies, adjuvants, and vaccines designed to activate immune response to cancers and infections, today announced acceptance of its abstract describing updated Phase 1 clinical trial results for AGEN1181 (Fc-enhanced anti-CTLA-4) alone and in combination with balstilimab (anti-PD-1) at the Society for Immunotherapy of Cancer (SITC)

The Daily Biotech Pulse: Adcom Tryst For Pfizer/BioNTech Booster Shot, AbCellera's COVID Antibody Treatment Gets Expanded Use, Protagonist Slapped With Clinical Hold
17 Sep, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Agenus' Combo Therapy Trial Shows Higher Responses In Cervical Cancer
17 Sep, 2021 FinancialContent

Agenus Inc(NASDAQ: AGEN)presented final resultsfrom the Bal/Zal combination study at the European Society for ...

Combination of Balstilimab Plus Zalifrelimab Doubles Responses in 2L Cervical Cancer in Data to Be Presented at ESMO
16 Sep, 2021 FinancialContent
Analysts Expect TUSA Will Reach $54
16 Sep, 2021 FinancialContent

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. For the First Trust Total US Market AlphaDEX ETF (TUSA), we found that the implied analyst target price for the ETF based upon its underlying holdings is $53.68 per unit.

Interesting AGEN Put And Call Options For January 2024
14 Sep, 2021 FinancialContent

Investors in Agenus Inc (AGEN) saw new options begin trading this week, for the January 2024 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 857 days until expiration the newly trading contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration..

New Agenus Subsidiary, SaponiQx, Builds Innovative Adjuvant Platform and Forms Collaboration with Ginkgo Bioworks
10 Sep, 2021 FinancialContent

Development of saponin molecules designed to provide high-efficacy and long-lasting protection for pandemic vaccines

Agenus to Participate in September Investor Conferences
09 Sep, 2021 FinancialContent
The Daily Biotech Pulse: VectivBio In M&A Mix, Sonnet Biotherapeutics Advances Candidate To Clinics, CEO Transitions At Galapagos, Talis Biomedical
31 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: MorphoSys-Incyte Snag European Nod, Immutep Granted Chinese Patent, Bolt Biotherapeutics Strike Oncology Collaboration
27 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

Balstilimab Monotherapy Data Published in Gynecologic Oncology
26 Aug, 2021 FinancialContent
The Daily Biotech Pulse: Lilly Strikes $1.6B R&D Collaboration, FSD Pulls Plug On COVID-19 Program, Cassava Sinks On Questions About Alzheimer's Drug
25 Aug, 2021 FinancialContent

ere's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting ...

The Daily Biotech Pulse: Cara's Korsuva Greenlighted By FDA, Clinical Trial Disappointments For Novartis, Theravance, Vertex Inks CRISPR Licensing Deal
24 Aug, 2021 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting ...

Stocks That Hit 52-Week Highs On Monday
16 Aug, 2021 FinancialContent

Before 10 a.m. ET on Monday, 71 companies hit new 52-week highs. Highlights: Apple (NASDAQ:AAPL) was the ...

Bullish: Analysts Just Made An Incredible Upgrade To Their Agenus Inc. (NASDAQ:AGEN) Forecasts
15 Aug, 2021 Yahoo! Finance

Shareholders in Agenus Inc. ( NASDAQ:AGEN ) may be thrilled to learn that the analysts have just delivered a major...

Hot Biotech Stocks That Deserve Your Attention In August 2021
11 Aug, 2021 FinancialContent
Why Agenus Fell by Over 4% on Monday
09 Aug, 2021 FinancialContent

Investors were spooked by some ugly numbers in the company's latest earnings report.

Agenus inc (AGEN) Q2 2021 Earnings Call Transcript
09 Aug, 2021 FinancialContent

AGEN earnings call for the period ending June 30, 2021.

Agenus (AGEN) Reports Q2 Loss, Misses Revenue Estimates
09 Aug, 2021 Yahoo! Finance

Agenus (AGEN) delivered earnings and revenue surprises of -54.17% and -36.75%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Agenus Inc (AGEN) is a NASDAQ Common Stock listed in , ,

970x250